Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease-Reference-Cited by-同舟云学术

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease

Published:2017-06 Issue: Volume:5 Page:241-258
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Huang Ju,Khan Aneal,Au Bryan C.,Barber Dwayne L.,López-Vásquez Lucía,Prokopishyn Nicole L.,Boutin Michel,Rothe Michael,Rip Jack W.,Abaoui Mona,Nagree Murtaza S.,Dworski Shaalee,Schambach Axel,Keating Armand,West Michael L.,Klassen John,Turner Patricia V.,Sirrs Sandra,Rupar C. Anthony,Auray-Blais Christiane,Foley Ronan,Medin Jeffrey A.

Funder

The Canadian Institutes of Health Research

Kidney Foundation of Canada

University of Calgary Cumming School of Medicine

Alberta Health Services

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference50 articles.

1. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency;Brady;N. Engl. J. Med.,1967

2. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy;Desnick;Ann. Intern. Med.,2003